This is a best-case data readout that substantially de-risks the gedatolisib program ahead of the July 17 PDUFA. The combination of superior efficacy (2x PFS) and better tolerability vs the current standard-of-care alpelisib positions gedatolisib for potential label expansion into the larger PIK3CA-mutant population. Monitor for sNDA submission timing and any FDA advisory committee meeting. The stock should re-rate upward on the probability of a broad commercial launch in Q3 2026.
Price Chart
Executive Summary
Celcuity announced detailed Phase 3 VIKTORIA-1 results showing its gedatolisib-triplet (gedatolisib + fulvestrant + palbociclib) doubled median progression-free survival to 11.1 months vs 5.6 months for alpelisib + fulvestrant (HR=0.50, p<0.0001) in PIK3CA-mutant HR+/HER2- advanced breast cancer, with a 48.9% objective response rate and lower discontinuation rates (2.6% vs 7.1%). The company also noted its existing NDA for the wild-type cohort is under Priority Review with a PDUFA date of July 17, 2026, and it plans to submit these data as an sNDA.
Key Facts
- Gedatolisib-triplet reduced risk of disease progression or death by 50% vs alpelisib + fulvestrant (HR=0.50; 95% CI: 0.37-0.68; p<0.0001)
- Median PFS: 11.1 months (gedatolisib-triplet) vs 5.6 months (alpelisib + fulvestrant)
- Objective response rate: 48.9% (gedatolisib-triplet) vs 26.0% (alpelisib + fulvestrant)
- Treatment discontinuation due to adverse events: 2.6% (gedatolisib-triplet) vs 7.1% (alpelisib + fulvestrant)
- FDA has granted Priority Review for NDA in PIK3CA wild-type ABC with PDUFA goal date of July 17, 2026
- Company plans to submit these data as an sNDA to FDA and to other regulatory authorities
- Company states it is on track for potential FDA approval and commercial launch in Q3 2026
Financial Impact
Transformative for a $6B market cap clinical-stage biotech — gedatolisib now has two positive Phase 3 readouts (WT and MT cohorts) with best-in-class efficacy and safety vs standard-of-care alpelisib, supporting a broad label in HR+/HER2- advanced breast cancer. Peak sales potential is multi-billion dollar if approved in both WT and MT populations.
Risk Factors
- FDA approval is not guaranteed despite Priority Review; a complete response letter would be severely negative
- Commercial launch execution risk for a first-time commercial-stage biotech
- Competition from other PI3K/AKT/mTOR inhibitors in development
- Overall survival data is still immature — a negative OS signal could limit label or uptake
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-026761 |
| Document: form8-k.htm | 0001493152-26-026761 |
| Document: 0001493152-26-026761-index-headers.html | 0001493152-26-026761 |
| Document: 0001493152-26-026761-index.html | 0001493152-26-026761 |
| Document: 0001493152-26-026761.txt | 0001493152-26-026761 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 26, 2026 5w ago | 8-K | $95.08 $84.00 | ▼ −11.65% | ▼ −12.86% | $72.51 (−23.74%) |
Jul 15, 2026 11w ago | 144 | $91.51 $92.08 | ▼ −0.62% | ▲ +1.72% | $72.51 (+20.76%) |
Jul 14, 2026 11w ago | Press Release | $91.51 $92.08 | ▲ +0.62% | ▼ −1.72% | $72.51 (−20.76%) |
Jun 11, 2026 16w ago | Institutional Cluster | $89.49 $113.51 | ▲ +26.84% | ▲ +24.95% | $72.51 (−18.97%) |
Jun 8, 2026 16w ago | 8-K | $92.59 $115.72 | ▲ +24.98% | ▲ +23.53% | $72.51 (−21.69%) |
Jun 5, 2026 17w ago | 424B5 | $88.28 $108.58 | ▲ +23.00% | ▲ +21.13% | $72.51 (−17.86%) |
Jun 4, 2026 17w ago | Press Release | $92.47 $107.95 | ▲ +16.74% | ▲ +18.11% | $72.51 (−21.59%) |
Jun 3, 2026 17w ago | Press Release | $88.95 $107.95 | ▼ −21.36% | ▼ −22.36% | $72.51 (+18.48%) |
Jun 3, 2026 17w ago | 424B5 | $88.95 $107.95 | ▼ −21.36% | ▼ −22.36% | $72.51 (+18.48%) |
Jun 2, 2026 17w ago | 8-K | $91.42 $104.49 | ▲ +14.30% | ▲ +15.86% | $72.51 (−20.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access